Copyright © 2013 Knight Sac Media. All rights reserved.http://www.siliconinvestor.com/subject.aspx?subjectid=37497This one will be fun...... Rigel Pharmaceuticals Announces Pricing of Initial Public Offering SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its initial public offering of 5,000,000 shares of common ...http://www.siliconinvestor.com/images/Logo380x132.pnghttp://www.siliconinvestor.com/subject.aspx?subjectid=3749738013210mopgcwChuckle, thanks appreciate the sympathy. time for a pint. hope all is well with you and yours over there. best.http://www.siliconinvestor.com/readmsg.aspx?msgid=288178534/5/2013 12:10:40 PMnigel bateshttp://www.siliconinvestor.com/readmsg.aspx?msgid=288177854/5/2013 11:47:46 AMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=288175444/5/2013 10:44:57 AMnigel bates"... interesting to see if the P3 yields a better answer next year." Not so much.... AstraZeneca today announced top-line results of OSKIRA-1, a Phase III study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKI...http://www.siliconinvestor.com/readmsg.aspx?msgid=288170894/5/2013 4:37:37 AMmopgcwi guess $9.50 was not too shabby now... it will be interesting to see if the P3 yields a better answer next year. tough blow. http://www.siliconinvestor.com/readmsg.aspx?msgid=2860233012/13/2012 4:22:07 PMmopgcwUPDATE 3-Hopes fade for AstraZeneca and Rigel's arthritis pill10:37 AM ET, 12/13/2012 - Reuters * Oral fostamatinib worse than Abbott injectable in Phase IIb * Definitive Phase III results with fostamatinib due in 2013 * Analysts' expectations for AstraZeneca, Rigel product low * AstraZeneca shares fall 3 percen...http://www.siliconinvestor.com/readmsg.aspx?msgid=2860149912/13/2012 11:12:31 AMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=2844897810/3/2012 10:43:43 AMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=283885309/6/2012 11:17:59 AMmopgcwSOUTH SAN FRANCISCO, Calif., June 19, 2012 /PRNewswire/ -- AstraZeneca and Rigel Pharmaceuticals, Inc. (RIGL), (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit IL-13 and IL-4 signaling, which ...http://www.siliconinvestor.com/readmsg.aspx?msgid=282183726/20/2012 5:06:31 PMtuckhttp://www.siliconinvestor.com/readmsg.aspx?msgid=281123654/28/2012 11:39:04 AMMiljenko Zuanichttp://www.siliconinvestor.com/readmsg.aspx?msgid=281119514/27/2012 10:24:09 PMtuckCompetition update from Portola's syk program portola.com  >> J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. Epub 2011 Oct 31.Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis. Coffey G, Deguzman F, Inagaki M, Pak Y, Delan...http://www.siliconinvestor.com/readmsg.aspx?msgid=279232582/2/2012 12:33:47 PMmopgcwhttp://www.siliconinvestor.com/readmsg.aspx?msgid=279113961/27/2012 7:58:56 PMmopgcw Rigel to Webcast Investor Day on October 13, 2011 Thu October 6, 2011 7:30 AM PR Newswire Calif., Oct. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. today announced that it will provide a live webcast of its upcoming Investor/Analyst Day on Thursday, October 13, 2011 at 10:00am EDT. Members of Rigel's seni...http://www.siliconinvestor.com/readmsg.aspx?msgid=2768833710/7/2011 4:49:46 PMmopgcw JPMorgan Starts Rigel Pharmaceuticals (RIGL) at Overweight 7:32 am ET 09/29/2011 - Street Insider JPMorgan initiates coverage on Rigel Pharmaceuticals (NASDAQ: RIGL) with an Overweight. PT $14.00. For more ratings news on Rigel Pharmaceuticals click here and for the rating history of Rigel Pharmaceuticals click here....http://www.siliconinvestor.com/readmsg.aspx?msgid=276687099/29/2011 10:32:42 AM